

Instructions for Authors 2019

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dagleish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iar@iar-anticancer.org) within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
 7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
 8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
 9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 66%).
 10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
 11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
 12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
 13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2019 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Contents*Review*

Reconstructive Surgery of Inguinal Hernia: A Systematic Literature Review of Surgical Etiology and Reconstructive Technique. K. SORELJUS, L. SCHIRALDI, S. GIORDANO, C.M. ORANGES, W. RAFFOUL, P.G. DI SUMMA (Uppsala, Sweden; Lausanne, Basel, Switzerland; Turku, Finland) 1

Lack of Awareness of Dietary Sources of Phosphorus Is a Clinical Concern. M. SHIMADA, Y. SHUTO-UCHITA, H. YAMABE (Hiroaki) (Nagasaki, Japan) 11

Clinical Relevance of Routine Monitoring of Patient-reported Outcomes Versus Clinician-reported Outcomes in Oncology. F. FITENI, A. CUENANT, N. FAVIER, C. COUSIN, N. HOUËDE (Nîmes; Montpellier, France) 17

Experimental Studies

Enriching Stem/Progenitor Cells from Dental Pulp Cells by Low-density Culturing. Y. ZHANG, V. ZHENG, W. EICHHORN, J. KLATT, A. HENNINGSEN, L. KLUMPE, R.E. FRIEDRICH, M. COSSAU, R. SMETS (Hamburg, Germany) 23

Gestational Diabetes and T-cell (Th1/Th2/Th17/Treg) Immune Profile. E. SIFNAIOS, G. MASTORAKOS, K. PSARBA, N.-D. PANAGOPOULOS, K. PANOLIS, N. VITORATOS, D. RIZOS, G. CREATSAS (Athens, Greece) 31

Overexpression of MicroRNA-1 in Prostate Cancer Cells Modulates the Blood Vessel System of an *In Vivo* Hen's Egg Test-Chorioallantoic Membrane Model. A. REUTER, A. SCHELL, L.-O. BRANDENBURG, M. BURCHARDT, A. FRAMER, M.B. STOFFE (Gießen/Leipzig, Rostock, Aachen, Germany) 41

Immunohistochemical Evidence of the Involvement of Natural Killer (CD161⁺) Cells in Spontaneous Regression of Lung Rat Sarcomas. J. BOJALESSA, M. CIERVINKOVA, E. CHMELIKOVA, D. PLANSKA, J. CIZKOVA, V. HORAK (Liberec; Prague, Czech Republic) 47

Content continued on the back cover

ISSN (online): 1791-7549

General Policy

- **IN VIVO** is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.
- The principal aim of **IN VIVO** is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance (3 months from submission).
- **Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

- **E-mail:** journals@iia-anticancer.org; IIAR WEBSITES: www.iia-anticancer.org and www.iiajournals.org

- **International Journal of Experimental and Clinical Pathophysiology and Drug Research**
- **Published bimonthly by the International Institute of Anticancer Research**
- **Available online only and open access with Stanford University HighWire Press**

● Selection of Recent Articles

Amelioration of Amyotrophic Lateral Sclerosis (ALS) in SOD1^{G93A} Mice by Transplanted Marrow Origin M₂ Microglia. M.W. EPPERLY, R. FISHER, L. RIGATTI, S. WATKINS, X. ZHANG, W. HOU, D. SHIELDS, D. FRANICOLA, H. BAYIR, H. WANG, S. THERMOZIER, A. HENDERSON, C. DONNELLY, P. WIPF, J.S. GREENBERGER (Pittsburgh, PA, USA)

A Simple and Easily Reproducible Model of Reversible Obstructive Jaundice in Rats. S. HIRATANI, R. MORI, Y. OTA, R. MATSUYAMA, T. KUMAMOTO, Y. NAGASHIMA, D. MORIOKA, I. ENDO (Yokohama, Japan)

Perioperative Management in Patients With Undergoing Direct Oral Anticoagulant Therapy in Oral Surgery – A Multicentric Questionnaire Survey. C. PRECHT, Y. DEMIREL, A.T. ASSAF, H.O. PINNSCHMIDT, C. KNIPFER, H. HANKEN, R.E. FRIEDRICH, J. WIKNER (Hamburg, Germany)

Cytotoxicity and Pro-inflammatory Properties of Aliphatic Alpha, Beta-unsaturated Acid and Ester Monomers in RAW264.7 Cells and Their Chemical Reactivity. Y. MURAKAMI, A. KAWATA, S. SUZUKI, S. FUJISAWA (Sakado, Japan)

Intra- and Postoperative Blood Flow Monitoring in a Sheep Model of Uterus Transplantation. A. KENGLBACH-WEIGAND, L. LOTZ, R. SCHMID, W. LANG, M.W. BECKMANN, I. HOFFMANN, R.E. HORCH, S.P. RENNER, R. DITTRICH, A.M. BOOS, T. HILDEBRANDT (Erlangen, Germany)

Three-dimensional Assessment of the Breast: Validation of a Novel, Simple and Inexpensive Scanning Process. C.M. ORANGES, S. MADDURI, P. BRANTNER, B. MSALLEM, S. GIORDANO, B. BENITEZ, D.F. KALBERMATTEN, D.J. SCHAEFER, F.M. THIERINGER (Basel; Allschwil, Switzerland; Turku, Finland)

Oxidative Stress and Oral Mucosal Diseases: An Overview. N. SARDARO, F. DELLA VELLA, M.A. INCALZA, D. DI STASIO, A. LUCCHESI, M. CONTALDO, C. LAUDADIO, M. PETRUZZI (Bari; Naples, Italy)

Reconstruction of Spinal Soft Tissue Defects With Perforator Flaps From the Paraspinal Region. P.G. DI SUMMA, R.D. LARGO, T. ISMAIL, M. TREMP, A. LUNGER, R. WETTSTEIN, S.M. KRÄHENBÜHL, S. GIORDANO, D.J. SCHAEFER, S. SCHAEAREN, D.F. KALBERMATTEN (Lausanne; Basel, Switzerland; Turku, Finland)

Mid- to Long-term Outcomes After Split-thickness Skin Graft vs. Skin Extension by Multiple Incisions. J.N. KERN, F. WEIDEMANN, P.F. O'LOUGHLIN, C. KRETTEK, R. GAULKE (Hanover, Germany; Cork, Ireland)

Clinicopathological Characteristics of Well-differentiated Papillary Mesothelioma of the Peritoneum: A Single-institutional Experience of 12 Cases. M. KIM, H.-S. KIM (Seoul, Republic of Korea)

Fistein Suppresses Human Osteosarcoma U-2 OS Cell Migration and Invasion via Affecting FAK, uPA and NF-κB Signaling Pathway In Vitro. J.-K. CHEN, S.-F. PENG, K.C. LAI, H.-C. LIU, Y.-P. HUANG, C.-C. LIN, A.-C. HUANG, F.-S. CHUEH, J.-G. CHUNG (Changhua; Taichung; Tainan; Yunlin; Yilan, Taiwan, ROC)

Definitive Radiotherapy for Older Patients Aged ≥75 Years With Localized Esophageal Cancer. G. SUZUKI, H. YAMAZAKI, N. AIBE, K. MASUI, T. KIMOTO, D. SHIMIZU, T. NISHIMURA, A. NAKASHIMA, K. MACHIDA, K. KAWABATA, Y. OTA, H. FUJIWARA, T. ISHIKAWA, K. YAMADA (Kyoto, Japan)

Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience. J.M. BYUN, S.-S. YOON, Y. KOH, I. KIM, J. JO, H. PARK, J.-O. LEE, J. LEE (<i>Seoul; Jeju; Seongnam, Republic of Korea</i>)	5165
Pretreatment Serum Levels of Soluble Cytokeratin Fragments (Cyfra 21-1, TPS, MonoTotal) in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas. D. KALFERT, J. LUDVIK, R. KUCERA, O. TOPOLCAN, P. CELAKOVSKY, M. PESTA, I. KHOLOVA, J. PLZAK, M. LUDVIKOVA (<i>Prague, Czech Republic; Tampere, Finland</i>).....	5171
The Role of Dimethoate and UV-B on Skin of Wistar Rats. T.R.M. DE OLIVEIRA FERNANDES, C.T. FUJIYAMA OSHIMA, L. CARDILI, D.A. RIBEIRO, M. SOUZA SILVA, J. PEDROSA KORINFISKY, H. PLAPLER (<i>Petrolina; Sao Paulo, Brazil</i>)	5179
Schwannoma of Foot and Ankle: Seven Case Reports and Literature Review. X. HAO, D. LEVINE, J. YIM, C. QI, L. FIRESTONE, I. BEISER, E. LEONE, K. WOELFFER, G. MIRKIN (<i>Rockville, MD, USA</i>)	5185
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors. K. ANDO, K. HAMADA, M. WATANABE, R. OHKUMA, M. SHIDA, R. ONOUE, Y. KUBOTA, H. MATSUI, T. ISHIGURO, Y. HIRASAWA, H. ARIIZUMI, J. TSURUTANI, K. YOSHIMURA, T. TSUNODA, S. KOBAYASHI, S. WADA (<i>Tokyo, Japan</i>)	5195
Outcome of Pediatric Acute Lymphoblastic Leukemia: Sixty Years of Progress. E. DEMIDOWIC, M. POGORZAŁA, M. ŁĘCKA, H. ŻOŁNOWSKA, A. MARJAŃSKA, M. KUBICKA, B. KURYŁO-RAFIŃSKA, K. CZYŻEWSKI, R. DĘBSKI, A. KOŁTAN, M. RICHERT-PRZYGOŃSKA, J. STYCZYŃSKI (<i>Bydgoszcz, Poland</i>).....	5203
Prevention of Anastomotic Leakage in Ovarian Cancer Debulking Surgery and Its Impact on Overall Survival. A. KOSCIELNY, A. KO, E.K. EGGER, W. KUHN, J.C. KALFF, M.-D. KEYVER-PAIK (<i>Bonn; Deggendorf, Germany</i>)	5209
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma. V. FONTANA, M.P. PISTILLO, A. VIGANI, P.A. CANESSA, G. BERISSO, U. GIANNONI, P. FERRO, M.C. FRANCESCHINI, R. CAROSIO, M. TONARELLI, C. ROSSI, P. DESSANTI, S. RONCELLA (<i>Genoa; La Spezia, Italy</i>).....	5219
Errata	5225
Book Reviews	5227
Announcements	5228

Diagnostic Accuracy of CYFRA21-1 in the Differential Diagnosis of Pleural Effusions. J. TRAPÉ, F. SANT, J. MONTESINOS, A. ARNAU, M. SALA, O. BERNADICH, E. MARTÍN, D. PERICH, J. LOPEZ, S. ROS, E. ESTEVE-VALVERDE, R. PÉREZ, C. GONZÁLEZ-FERNÁNDEZ, J. ALIGUE, S. CATOT, M. DOMENECH, D. RUIZ, M. BONET, R. MOLINA, J. ORDEIG (<i>Manresa; Barcelona, Spain</i>)	5071
Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment. L. KÄSMANN, J. TAUGNER, C. EZE, O. ROENGVORAPHOJ, M. DANTES, K. GENNEN, M. KARIN, O. PETRUKHNOV, A. TUFMAN, C. BELKA, F. MANAPOV (<i>Munich, Germany</i>)	5077
Keratinocyte Carcinoma and Risk for Another Type of Cancer: Assessment of a Dose-response Relationship. A. WILSON, J. SMALL, C. FLANAGAN, D. PERRY, R. MARCHELL, B. THIERS, A.J. ALBERG (<i>Charleston; Columbia, SC, USA</i>)	5083
Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis. Y. MORINE, T. IKEMOTO, S. IWAHASHI, Y. SAITO, S. YAMADA, C. TAKASU, J. HIGASHIJIMA, S. IMURA, M. SHIMADA (<i>Tokushima, Japan</i>)	5089
Surgical Strategy for Rectovaginal Fistula After Colorectal Anastomosis at a High-volume Cancer Center According to Image Type and Colonoscopy Findings. K. KOMORI, T. KINOSHITA, T. OSHIRO, A. OUCHI, S. ITO, T. ABE, Y. SENDA, K. MISAWA, Y. ITO, S. NATSUME, E. HIGAKI, M. OKUNO, T. HOSOI, T. NAGAO, A. KUNITOMO, S. OKI, J. TAKANO, Y. SUENAGA, S. MAEDA, H. DEI, Y. NUMATA, Y. SHIMIZU (<i>Nagoya, Japan</i>)	5097
Complete Pathological Response Following Radiochemotherapy for Locally Advanced Rectal Cancer: Short and Long-term Outcome. O. ISKANDER, L. COURTOT, N. TABCHOURI, A. ARTUS, N. MICHOT, O. MULLER, U. PABST-GIGER, P. BOURLIER, A. KRAEMER-BUCUR, T. LECOMTE, S. GUYETANT, S. CHAPET, G. CALAIS, E. SALAMÉ, M. OUAÏSSI (<i>Tours, France; Münster, Germany</i>)	5105
Soluble Interleukin-2 Receptor Level at Diagnosis Predicts Prognosis of Patients With Follicular Lymphoma Irrespective of Initial Management Strategy. M. YAMAMOTO, K. TANAKA, Y. UMEZAWA, T. NAGAO, S. TOYOTA, O. MIURA (<i>Tokyo; Kanagawa, Japan</i>)	5115
A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). S.R. PARK, D.H. YOON, J.H. KIM, Y.-H. KIM, H.R. KIM, H.J. LEE, H.-Y. JUNG, G.-H. LEE, H.J. SONG, D.H. KIM, K.D. CHOI, J.H. LEE, J.Y. AHN, J.-S. RYU, K.-J. CHO, S.-B. KIM (<i>Seoul, Republic of Korea</i>)	5123
Overall Survival of Patients With Locoregional and Metastatic Breast Cancer: Is the Influence of Baseline Characteristics the Same? I. GOMES, P. AGUIAR, A. MIRANDA, C. NUNES (<i>Lisbon; Porto Salvo, Portugal</i>)	5135
Assessment of Outcome of Hepatic Resection for Extremely Elderly Patients With a Hepatic Malignancy. T. HORIUCHI, K. HARUKI, H. SHIBA, T. SAKAMOTO, N. SAITO, Y. SHIRAI, R. IWASE, Y. FUJIWARA, K. YANAGA (<i>Tokyo, Japan</i>)	5143
Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. A. TAKAHASHI, M. MORIGUCHI, Y. SEKO, H. ISHIKAWA, T. YO, H. KIMURA, H. FUJII, T. SHIMA, Y. MITSUMOTO, H. ISHIBA, H. TAKASHIMA, Y. NAGAO, M. JO, M. ARAI, T. HARA, A. OKAJIMA, A. MURAMATSU, A. MORITA, N. YOSHINAMI, T. NAKAJIMA, H. MITSUYOSHI, A. UMEMURA, T. NISHIKAWA, K. YAMAGUCHI, Y. ITOH (<i>Kyoto; Shiga; Osaka; Hyogo, Japan</i>)	5149
Change in PMI During Neoadjuvant Therapy Is a Predictive Prognostic Marker in Rectal Cancer. T. FUKUOKA, K. MAEDA, H. NAGAHARA, M. SHIBUTANI, Y. ISEKI, S. MATSUTANI, K. HIRAKAWA, M. OHIRA (<i>Osaka, Japan</i>)	5157

Increased Risk of Breast and Uterine Cancer Among Women With Ovarian Granulosa Cell Tumors. D. NASIOUDIS, E. WILSON, S.A. MASTROYANNIS, G. SISTI, A.F. HAGGERTY, E.M. KO, N.A. LATIF (Philadelphia, PA, USA; Florence, Italy)	4971
Lymph Node Metastases Diagnosed by ¹⁸ F-FDG-PET/CT in Esophageal Squamous Cell Cancer Treated With Concurrent Chemoradiotherapy. I. OGINO, S. WATANABE, T. MISUMI, M. HATA, C. KUNISAKI (Yokohama, Japan).....	4977
Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy. D. HARADA, K. TAKATA, S. MORI, T. KOZUKI, Y. TAKECHI, S. MORIKI, Y. ASAKURA, T. OHNO, N. NOGAMI (Matsuyama; Okayama, Japan)	4987
Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma. D. ZIPPEL, O. FRIEDMAN-ELDAR, S. RAYMAN, D. HAZZAN, A. NISSAN, G. SCHTRECHMAN, G. MARKEL, J. SCHACHTER, O. ITZHAKI, M.J. BESSER (Ramat Gan; Tel Aviv, Israel)	4995
Incorporating Bortezomib in the Management of Plasmablastic Lymphoma. O. UMEANAETO, J. GAMBOA, J. DIAZ, M.N. HAKIM, J. CORRAL, A. PHILIPOVSKIY, S. GAUR (El Paso, TX, USA)	5003
High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer. N. INOUE, W. LI, Y. FUJIMOTO, Y. MATSUSHITA, T. KATAGIRI, H. OKAMURA, Y. MIYOSHI (Nishinomiya; Tokushima, Japan)	5009
Prediction of Portal Vein Thrombosis Following Hepatectomy for Perihilar Cholangiocarcinoma: Efficacy of Postoperative Portal Vein Diameter Ratio and Angle. T. UCHIDA, Y. YAMAMOTO, T. SUGIURA, Y. OKAMURA, T. ITO, R. ASHIDA, K. OHGI, T. ARAMAKI, K. UESAKA (Shizuoka, Japan).....	5019
Which Factors Affect Survival in Patients With Upper Limb Osteosarcoma? D.J. RESTREPO, M.T. HUAYLLANI, D. BOCZAR, A. SISTI, A.C. SPAULDING, R.E. CARTER, S.L. MORAN, A.S. PARKER, G. PERDIKIS, A.J. FORTE (Jacksonville, FL; Rochester, MN; Nashville, TN, USA).....	5027
Does Robotic Distal Gastrectomy Facilitate Minimally Invasive Surgery for Gastric Cancer? T. KUBOTA, D. ICHIKAWA, T. KOSUGA, K. SHODA, S. KOMATSU, H. KONISHI, A. SHIOZAKI, H. FUJIWARA, K. OKAMOTO, E. OTSUJI (Kyoto; Yamanashi, Japan)	5033
Efficacy of Adjuvant Chemotherapy According to the Classification of Recurrence Risk Based on Systemic Inflammatory Markers in Patients With Liver Metastases of Colorectal Cancer. M. SHIBUTANI, H. NAGAHARA, T. FUKUOKA, Y. ISEKI, K. HIRAKAWA, M. OHIRA (Osaka, Japan)	5039
Cystic Lateral Neck Lesions: Etiologic and Differential Diagnostic Significance in a Series of 133 Patients. A. FRANZEN, T. GÜNZEL, A. BUCHALI, A. COORDES (Neuruppin; Leer; Berlin, Germany).....	5047
Metastatic Bilateral Strumal Carcinoid: A Case Report and Review of the Literature. M. BORGHESE, P. RAZZORE, A. FERRERO, L. DANIELE, L.L. MARIANI, L.G. SGRO, G. DE ROSA, N. BIGLIA (Turin, Italy).....	5053
Feasibility of Identifying Patients at High Risk of Hereditary Gastric Cancer Based on Clinicopathological Variables. S. NISHIMURA, M. YASHIRO, T. SERA, Y. YAMAMOTO, Y. KUSHITANI, A. SUGIMOTO, S. KUSHIYAMA, K. KURODA, S. TOGANO, T. OKUNO, T. TAMURA, T. TOYOKAWA, H. TANAKA, K. MUGURUMA, K. HIRAKAWA, M. OHIRA (Osaka, Japan).....	5057
Accelerated Middle Half Body Radiotherapy in Bone Metastases from Prostate Cancer: A Phase I Study (SHARON Project). A. ZAMAGNI, M. BUWENGE, G. MACCHIA, G. SIEPE, S. CILLA, F. CELLINI, A. ARCELLI, E. FARINA, F. DEODATO, S. CAMMELLI, A.G. MORGANTI (Bologna; Campobasso; Rome; Cotignola, Italy)	5065

Clinical Studies

Effects of Colorectal Cancer Risk Factors on the Association Between Aspirin and Colorectal Cancer. M.E. SEATON, U. PETERS, K.C. JOHNSON, C. KOOPERBERG, A. BAFFORD, N. ZUBAIR (<i>Baltimore, MD; Seattle, WA; Memphis, TN, USA</i>).....	4877
Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. G. LOGANADANE, B.H. KANN, H.S. PARK, S.B. JOHNSON, S. MEHRA, B.L. JUDSON, A. BHATIA, Y. BELKACEMI, W.G. YARBROUGH, B. BURTNES, Z.A. HUSAIN (<i>New Haven, CT; Chapel Hill, NC, USA; Créteil Cedex, France; Toronto, ON, Canada</i>).....	4885
The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. D. TONG, A. CONSTANTINIDOU, B. ENGELMANN, F. CHAMBERLAIN, K. THWAY, C. FISHER, A. HAYES, N. FOTIADIS, C. MESSIOU, A.B. MIAH, S.H. ZAIDI, C. BENSON, W. VAN DER GRAAF, R.L. JONES (<i>London, UK; Nicosia, Cyprus</i>).....	4891
Intrauterine Progestin Therapy as a New Approach to Premalignant Endometrial Polyps: A Prospective Observational Study. E. THORESEN SLETTEN, M. ARNES, A.B. VEREIDE, A. ØRBO (<i>Tromsø, Norway</i>)	4897
Solitary Cerebral Metastases vs. High-grade Gliomas: Usefulness of Two MRI Signs in the Differential Diagnosis. C.F. MUCCIO, E. TEDESCHI, L. UGGA, R. CUOCOLO, G. ESPOSITO, F. CARANCI (<i>Benevento; Naples; Campobasso, Italy</i>)	4905
Somatic Transformation in Metastatic Testicular Germ Cell Tumours – A Different Disease Entity. A. SHARMA, C. ALIFRANGIS, M. MILIC, M. HALL, N. VASDEV, P. WILSON, A. GOGBASHIAN, D. HROUDA, D. BERNEY, J. SHAMASH (<i>Northwood; London; Stevenage, UK</i>).....	4911
Correlation of Tumor Location to Clinical Outcomes in Colorectal Cancer: A Single-institution Retrospective Analysis. C. SIGNORELLI, M.G. CHILELLI, I. SPERDUTI, S. GIACINTI, P.M. AMODIO, R. MACARONE PALMIERI, T.V. RANALLI, V.V. GOMES, M.E. ROSETTO, F. NELLI, E.M. RUGGERI (<i>Viterbo; Rome, Italy</i>).....	4917
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma. E.J.M. KARI, M.E.L. KUUSISTO, J. BÖHM, K.-M. HAAPASAARI, H.-R. TEPPU, P. KARIHTALA, A. HAKALAHTI, T. TURPEENNIEMI-HUJANEN, O. KUITTINEN (<i>Oulu; Jyväskylä; Kuopio, Finland</i>)	4925
Genetic Variants of the <i>IL2</i> Gene Related to Risk and Survival in Patients With Colorectal Cancer. J. DIMBERG, L. SHAMOON, K. LANDERHOLM, R.E. ANDERSSON, B. KOLODZIEJ, D. WÄGSÄTER (<i>Jönköping; Uppsala; Linköping, Sweden</i>).....	4933
Characteristics of Breast Cancer Patients Who Refuse Surgery. D.J. RESTREPO, A. SISTI, D. BOCZAR, M.T. HUAYLLANI, J. FISHE, E. GABRIEL, S.A. MCLAUGHLIN, S. BAGARIA, A. SPAULDING, B.D. RINKER, A.J. FORTE (<i>Jacksonville, FL, USA</i>)	4941
Tumor-specific Expression of Insulin-like Growth Factor II mRNA-binding Protein 3 Independently Predicts Worse Survival of Patients With Adenocarcinoma of the Ampulla of Vater. H.G. KIM, M.-S. PARK, J.-Y. SUNG, Y.W. KIM, H.-S. KIM, K. NA (<i>Seoul, Republic of Korea</i>).....	4947
The Influence of Adjuvant Radiotherapy and Single Nucleotide Polymorphisms on Circulating Immune Response Cell Numbers and Phenotypes of Patients With Breast Cancer. N. LAYTRAGOON LEWIN, T. LUETRAGOON, L. SHAMOON, D. OLIVA, B.-Å. ANDERSSON, S. LÖFGREN, L.E. RUTQVIST, F. LEWIN (<i>Jönköping; Linköping; Stockholm, Sweden; Phitsanulok, Thailand</i>)	4957
The Normal Epithelium of Crypts Accruing Below Nonpolypoid Adenomas Thrives With Relocated Proliferating Cell-domains and p53-Up-regulated Cells. C.A. RUBIO, P.T. SCHMIDT (<i>Stockholm, Sweden</i>)	4965

Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples. I. MARTÍN, B. NAVARRO, C. SOLANO, M. CALABUIG, J.C. HERNÁNDEZ-BOLUDA, P. AMAT, M.J. REMIGIA, F. GARCÍA, E. VILLAMÓN, M. TORMO (<i>Valencia, Spain</i>).....	4757
Association of Caspase-8 Genotypes With Bladder Cancer Risk. M. CHEN, Y.-T. TSAI, W.-S. CHANG, L.-C. SHIH, T.-C. SHEN, M.-L. LIN, C.-Y. CHAO, Y.-C. WANG, C.-W. TSAI, D.-T. BAU (<i>Beijing, PR China; Taichung, Taiwan, ROC</i>)	4767
Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. T. KIYUNA, Y. TOME, K. MIYAKE, T. MURAKAMI, H. OSHIRO, K. IGARASHI, K. KAWAGUCHI, J. HSU, M. SINGH, Y. LI, S. NELSON, M. BOUVET, S.R. SINGH, F. KANAYA, R.M. HOFFMAN (<i>San Diego; Los Angeles, CA; Frederick, MD, USA; Okinawa, Japan</i>).....	4775
Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model. T. HIGUCHI, N. SUGISAWA, K. MIYAKE, H. OSHIRO, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, K. IGARASHI, Z. KLINE, P. BELT, S.P. CHAWLA, M. BOUVET, S.R. SINGH, H. TSUCHIYA, R.M. HOFFMAN (<i>San Diego; Santa Monica, CA; Frederick, MD, USA; Kanazawa, Japan</i>)	4781
M-CSF Receptor Antagonists Inhibit the Initiation and Progression of Hepatocellular Carcinoma in Mice. Y. AKAZAWA, H. KONO, M. HARA, S. FURUYA, Y. NAKATA, H. WAKANA, H. FUKUSHIMA, C. SUN, H. FUJII, D. ICHIKAWA (<i>Yamanashi, Japan</i>)	4787
Thioredoxin-interacting Protein (TXNIP) Mediates Thioredoxin-dependent Antioxidant Mechanism in Endometrial Cancer Cells Treated With 1 α ,25-dihydroxyvitamin D ₃ . Y. KIM, Y.-S. KIM, M. KIM, J.-M. KIM, H.-H. LEE, T.-H. KIM (<i>Asan; Bucheon, Republic of Korea</i>)	4795
Ro 90-7501 Is a Novel Radiosensitizer for Cervical Cancer Cells that Inhibits ATM Phosphorylation. K. TAMARI, K. SANO, Z. LI, Y. SEO, K. OTANI, S. TATEKAWA, M. TORATANI, Y. TAKAOKA, Y. TAKAHASHI, K. MINAMI, F. ISOHASHI, M. KOIZUMI, K. OGAWA (<i>Osaka, Japan</i>)	4805
Blockade of γ -Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells. H. TAKAGI, H. II, S. KAGEYAMA, E. HANADA, K. TANIGUCHI, T. YOSHIYA, T. CHANO, A. KAWAUCHI, S. NAKATA (<i>Kyoto; Otsu; Osaka, Japan</i>)	4811
Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. T. SANOMACHI, S. SUZUKI, K. TOGASHI, S. SEINO, T. YOSHIOKA, C. KITANAKA, M. OKADA, M. YAMAMOTO (<i>Yamagata, Japan</i>).....	4817
mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both <i>In Vitro</i> and <i>In Vivo</i> . H.-F. LIAO, Y.-Z. LIN, C.-C. YU, T.-S. TAI, S.-K. HUNG, C.-C. YANG, Y.-C. SU (<i>Chiayi; Kaohsiung; Tainan, Taiwan, ROC</i>)	4829
Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma <i>In Vitro</i> . K. INTUYOD, C. HAHNVAJANAWONG, P. PINLAOR, S. PINLAOR (<i>Khon Kaen, Thailand</i>)	4837
Triorganotin Isothiocyanates Affect Migration and Immune Check-point Receptors in Human Triple-negative Breast Carcinoma MDA-MB-231 Cells. L. HUNAKOVA, E. HORVATHOVA, P. GRONESOVA, P. BOBAL, J. OTEVREL, J. BRTKO (<i>Bratislava, Slovak Republic; Brno, Czech Republic</i>)	4845
Biological Characteristics and Clinical Significance of ITGB1 and RHOC in Patients With Recurrent Colorectal Cancer. Y.J. HA, K.H. TAK, S.-K. KIM, C.W. KIM, J.L. LEE, S.A. ROH, D.-H. CHO, S.-Y. KIM, Y.S. KIM, J.C. KIM (<i>Seoul; Daejeon; Daegu, Republic of Korea</i>)	4853
Hypoxia-induced PGC-1 α Regulates Mitochondrial Function and Tumorigenesis of Colorectal Cancer Cells. C.W. YUN, J.H. LEE, S.H. LEE (<i>Seoul; Cheonan, Republic of Korea</i>)	4865

Immune Check Point CD40–CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells. R.M. HILLEBRAND, A. VOGT, C.P. STRASSBURG, M.A. GONZALEZ-CARMONA, I.G.H. SCHMIDT-WOLF (<i>Bonn, Germany</i>)	4643
Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatin, Overcome Cisplatin-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma. T. HIGUCHI, H. OSHIRO, K. MIYAKE, N. SUGISAWA, Q. HAN, Y. TAN, J. PARK, Z. ZHANG, S. RAZMJOOEI, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, K. IGARASHI, M. BOUVET, S.P. CHAWLA, S.R. SINGH, H. TSUCHIYA, R.M. HOFFMAN (<i>San Diego; Santa Monica, CA; Frederick, MD, USA; Kanazawa, Japan</i>)	4653
Antiproliferative Effects of Short-chain Fatty Acids on Human Colorectal Cancer Cells <i>via</i> Gene Expression Inhibition. T. OHARA, T. MORI (<i>Fukushima, Japan</i>)	4659
Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatin in a Patient-derived Orthotopic Xenograft Mouse Model. H. OSHIRO, Y. TOME, T. KIYUNA, S.N. YOON, T.M. LWIN, Q. HAN, Y. TAN, K. MIYAKE, T. HIGUCHI, N. SUGISAWA, Y. KATSUYA, J.H. PARK, Z. ZANG, S. RAZMJOOEI, M. BOUVET, B. CLARY, S.R. SINGH, F. KANAYA, K. NISHIDA, R.M. HOFFMAN (<i>San Diego, CA; Frederick, MD, USA; Okinawa, Japan</i>)	4667
High Sensitivity to Cholic Acid-induced Colonic Tumorigenesis Makes Female PIRC Rats (F344/NTac-Apc ^{am1137}) A Suitable Model for Studying CRC-promoting Agents. C. LUCERI, A.P. FEMIA, M. D'AMBROSIO, G. CADERNI (<i>Florence, Italy</i>)	4673
S100A8 Expression May Have Prognostic Value in CCRCC Reflecting TNM Staging and Fuhrman Nuclear Grade. H.J. AN, H.M. KOH, D.H. SONG (<i>Changwon; Jinju, Republic of Korea</i>).....	4681
Propagermanium Induces NK Cell Maturation and Tends to Prolong Overall Survival of Patients With Refractory Cancer. S. KIKUCHI, K. NOGUCHI, K. WAKAI, Y. HAMAZAKI, K. TOZAWA, T. JOMORI, M. SASAKO, H. MIWA (<i>Nishinomiya; Kyoto; Nagoya, Japan</i>)	4687
Metformin Prevents Peritoneal Dissemination <i>via</i> Immune-suppressive Cells in the Tumor Microenvironment. T. HIRAYAMA, Y. NAGATA, M. NISHIDA, M. MATSUO, S. KOBAYASHI, A. YONEDA, K. KANETAKA, H. UDONO, S. EGUCHI (<i>Nagasaki; Okayama, Japan</i>).....	4699
Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human <i>EGFR</i> -mutated Lung Cancers and <i>HER2</i> Gene-amplified Gastric Cancers in Mice. A. ITO, H. NAKANISHI, M. YOSHIMURA, S. ITO, Y. SAKAO, Y. KODERA, Y. YATABE, N. KANEDA (<i>Nagoya; Tokyo, Japan</i>)	4711
The Effects of Analgesics and Local Anesthetics on Gene Transcription Mediated by NFATc2 and Sp1 in Pancreatic Carcinoma. M. MALSY, B. GRAF, A. BUNDSCHERER (<i>Regensburg, Germany</i>)	4721
<i>Amphiregulin/epiregulin</i> mRNA Expression and Primary Tumor Location in Colorectal Cancer. H. KURAMOCHI, G. NAKAJIMA, K. HAYASHI, T. ARAIDA, M. YAMAMOTO (<i>Chiba; Tokyo, Japan</i>).....	4729
Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model. T. HARA, H. MIYAKE, N. HINATA, M. FUJISAWA (<i>Kobe; Hamamatsu, Japan</i>)	4737
Characterization of Telomerase (<i>hTERT</i>) in Solid and Hematopoietic Cancer Cell Lines Reveals Different Expression Patterns. L.S. DE HOLANDA, F.P. MESQUITA, M.O. DE MORAES-FILHO, M.E.A. DE MORAES, R.C. MONTENEGRO, A.J.D.S. PORTILHO, C.A. MOREIRA-NUNES (<i>Fortaleza, Brazil</i>)	4743
Comparison of Pregnane X Receptor Antagonists for Enhancing the Antitumor Effect of Cisplatin. M. YASUDA, S. KISHIMOTO, M. AMANO, S. FUKUSHIMA (<i>Kobe, Japan</i>).....	4749